KontRASt-06: An Open-label Phase II Trial Evaluating the Activity and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C-mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
Latest Information Update: 18 Apr 2025
At a glance
- Drugs Opnurasib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms KontRASt-06
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
Most Recent Events
- 20 May 2024 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Study design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 19 Apr 2023 Trial design presented at the 114th Annual Meeting of the American Association for Cancer Research.